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Mitochondrial DNA (mtDNA) is susceptible to oxidative stress and mutation. Few 
epidemiological studies have assessed the relationship between mtDNA copy number (mtDNAcn) 
and risk of colorectal cancer (CRC), with inconsistent findings. In this study, we examined the 
association between pre-diagnostic leukocyte mtDNAcn and CRC risk in a case-control study of 
324 female cases and 658 matched controls nested within the Nurses’ Health Study (NHS). 
Relative mtDNAcn in peripheral blood leukocytes was measured by quantitative PCR-based 
assay. Conditional logistic regression models were applied to estimate odds ratios (ORs) and 
95% confidence intervals (95% CIs) for the association of interest. Results showed lower log-
mtDNAcn was significantly associated with increased risk of CRC, in a dose-dependent 
relationship (P for trend < 0.0001). Compared to the 4th quartile, multivariable-adjusted OR 
(95% CI) was 1.10 (0.69, 1.76) for the 3rd quartile, 1.40 (0.89, 2.19) for the 2nd quartile, and 2.19 
(1.43, 3.35) for the 1st quartile. In analysis by anatomic subsite of CRC, we found a significant 
inverse association for proximal colon cancer [lowest vs. highest quartile, multivariable-adjusted 
OR (95% CI) = 3.31 (1.70, 6.45), P for trend = 0.0003]. Additionally, stratified analysis 
according to the follow-up time since blood collection showed that the inverse association 
between mtDNAcn and CRC remained significant among individuals with ≥ 5 years’ follow-up, 
and marginally significant among those with ≥ 10 years’ follow-up since mtDNAcn testing, 
suggesting that mtDNAcn may serve as a long-term predictor for risk of CRC. In conclusion, 
pre-diagnostic leukocyte mtDNAcn was inversely associated with CRC risk. Further basic 
experimental studies are needed to explore the underlying biological mechanisms linking 
mtDNAcn to CRC carcinogenesis.  
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Summary: Pre-diagnostic leukocyte mitochondrial DNA copy number, a reflection of oxidative 
stress damage, was inversely associated with risk of colorectal cancer, and may be a long-term 






















Colorectal cancer (CRC) is the third most common cancer among men and women in the 
U.S.(1). Across worldwide, CRC is the third most common cancer in men and the second most
common cancer in women (2). The incidence and mortality of CRC have been decreasing over 
the past decade, likely due in part to the successful implementation of screening programs (3). 
However, the disease is still the third leading cause of cancer death in the U.S. and the fourth 
across the world among men and women (1,2), posing an enormous health and socioeconomic 
burden (4). Thus, identifying biomarkers for CRC risk that might inform prevention and early 
diagnosis is of great public health importance. 
Mitochondria are essential eukaryotic organelles containing their own genome, i.e., 
mitochondrial DNA (mtDNA), which is usually maternally inherited (5). MtDNA consists of 
approximately 16,569 bp double-stranded circular DNA and encodes only thirty-seven genes. 
Most mammalian cells contain between hundreds and over a thousand mitochondria per cell, and 
each mitochondrion has two to ten copies of mtDNA (5). Compared to nuclear DNA, mtDNA 
has a higher mutation rate and is particularly susceptible to oxidative stress, probably due to its 
proximity to the source of reactive oxygen species (ROS) and its lack of protective histones (6). 
Though the study of mtDNA repair pathways has lagged behind inquiries into nuclear DNA 
repair mechanisms, research has not only shown the existence of robust damage tolerance 
mechanisms in mitochondria, but also proposed various mtDNA repair pathways that may 
properly maintain the mitochondrial genome (7).  
CRC is a heterogeneous disease associated with environmental and genetic factors 
through complicated interactions (8,9). Oxidative stress triggered by ROS may initiate and 





















damage, gene mutations, and genomic instability (10,11). Because mtDNA copy number 
(mtDNAcn) is a major biomarker for oxidative DNA damage and mitochondrial dysfunction, it 
has been hypothesized that altered pre-diagnostic leukocyte mtDNAcn may be associated with 
risk of developing cancers, including CRC.  
The few epidemiological studies that have assessed the relationship between mtDNAcn 
and risk of CRC have yielded inconsistent findings (12-14). A retrospective case-control study 
conducted by Qu et al. in a hospital setting in China first reported a positive association between 
mtDNAcn and CRC risk (12). Later, prospective case-control studies nested within the Shanghai 
Women’s Health Study (SWHS) (13) reported an inverse association, and the Singapore Chinese 
Health Study (SCHS) (14) reported a U-shaped relationship. Evidence supporting the 
relationship between mtDNAcn and CRC risk in western populations has been lacking. 
Therefore, in this study we examined the association between pre-diagnostic leukocyte 
mtDNAcn and the risk of CRC in a case-control study of 324 CRC cases and 658 matched 
healthy controls nested within the Nurses’ Health Study (NHS), a long-term prospective cohort 
study of women in the US.  
METHODS 
Study population 
 The Nurses’ Health Study was initiated in 1976, when 121,700 female US registered nurses 
aged 30-55 years completed and returned questionnaires regarding their medical histories and 
baseline lifestyles. Biennially, participants completed self-administered follow-up questionnaires 
with updated information on their dietary habits and other lifestyle factors, medical history, and 
disease diagnosis. In 1989-1990, a total of 32,826 participants in the NHS provided blood 





















Colorectal cancer case ascertainment and control selection 
CRC diagnoses were based on the self-report by nurses on biennial questionnaires and 
then confirmed by a pathologist. All CRC cases were incident cases diagnosed after blood 
collection. In this nested case-control study, we randomly selected 1-3 controls from the same 
cohort (NHS) of participants who were free of cancer (excluding non-melanoma skin cancer) up 
to and including the questionnaire cycle in which the case was diagnosed. Control subjects were 
matched to each case based on year of birth (±1 year), race, and fasting status at blood collection. 
A total of 324 CRC cases and 658 healthy controls were included. The study protocol was 
approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard 
T.H. Chan School of Public Health, and those of participating registries as required.  
Assessment of mtDNAcn  
Details of the ascertainment and validation of leukocyte mtDNAcn for blood samples from 
the NHS participants and quality control procedures were described previously (16-18). More 
detail can be found in Supplementary Methods. Briefly, genomic DNA was extracted from the 
buffy-coat leukocytes in peripheral blood, according to the QIAmp (Qiagen, CA, USA) 96-spin 
blood protocol. Concentrations of DNA were measured by pico-green quantitation utilizing a 
Molecular Devices 96-well spectrophotometer. The quantitative Polymerase Chain Reaction 
(qPCR)-based assay was used to determine the ratio of the copy numbers of mitochondrial ND2 
gene to genomic single-copy gene (AluYb8) (N/S), which is proportional to the average number 
of mtDNAcn. The relative N/S ratio was then calculated by subtracting the N/S ratio of the 
calibrator DNA from the N/S ratio of each sample. The value of mtDNAcn was calculated as the 





















(QC) samples were included. The coefficients of variation (CVs) for ND2 and AluYb8 were less 
than 1% among QC samples.  
Assessment of covariates 
Covariate data were collected through self-administered questionnaires at baseline (1976) 
and during follow-up biennially. In this study, we used covariates data from the questionnaire 
cycle closest to blood collection (1989-1990), including body mass index (BMI) calculated as 
height (m)/weight (kg)2, smoking status, alcohol consumption, Alternate Healthy Eating Index 
(AHEI), physical activity, family history of CRC, regular use of aspirin and other non-steroidal 
anti-inflammatory drugs (NSAIDs), parity as well as menopausal status and postmenopausal 
hormone use. Specifically, height and weight were collected at baseline and then weight was 
updated at each biennial questionnaire; we used height at baseline and weight at blood collection 
to calculate BMI. We also included weight change from blood collection until two years before 
diagnosis of the cases and same cycle of their matched controls into the multivariable model; to 
minimize reverse causality of CRC on weight, we excluded the two years before diagnosis for 
the calculation of weight change. Participants who used aspirin (either standard or low-dose) at 
least 2 times/week on average were classified as regular aspirin users. Regular users of non-
aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) were participants who responded “yes” 
to regular use on questionnaires, defined as at least 2 times/week (19). Physical activity was 
represented by metabolic equivalent (MET)-hours/week. Specifically, each activity was assigned 
a MET value, which refers to the metabolic rates for each specific activity divided by metabolic 
rates at rest. MET-hours/week for each activity was calculated by multiplying average time per 
week in each activity by the MET of each activity. Then total MET-hours per week was derived 





















(AHEI) is a dietary score (0-100 points) measuring the adherence to a dietary pattern 
characterized by foods and nutrients most predictive of risk of diseases; higher AHEI indicates 
healthier dietary quality. Foods/nutrients involved in AHEI development include whole grains, 
sugar-sweetened beverages, fruit juice, vegetables, fruits, nuts and legumes, red and processed 
meat, poly-unsaturated fatty acids, trans fats, long-chain (n-3) fats (EPA + DHA), and sodium 
(21). AHEI used in the current study was derived from the food frequency questionnaire at blood 
collection. The validity and reproducibility of physical activity and dietary information from the 
food frequency questionnaire have been reported elsewhere (22,23). 
Statistical analysis 
Log-transformed mtDNA copy numbers [log (mtDNAcn)] of cases and controls were 
stratified into four categories based on the quartiles of log (mtDNAcn) among all controls. 
Conditional logistic regression was applied to estimate the odds ratio (OR) and 95% confidence 
interval (CI) for the association of log (mtDNAcn) with CRC risk. Two models were analyzed: 
Model 1, the crude model without covariate adjustment; and Model 2, the multivariable model 
that adjusted for potential confounders, including BMI (in tertiles: 0-23.2 kg/m2, 23.2-26.6 
kg/m2, ≥ 26.6 kg/m2), physical activity (in tertiles, 0-8.2, 8.2-20.2, ≥ 20.2 MET-hours/week), 
smoking status (never, former, or current smokers), alcohol consumption (in tertiles, 0-0.8 g, 0.8-
5.8 g, ≥ 5.8 g per day), menopausal status and postmenopausal hormone use (premenopausal, 
never and former users, current users), parity (0/1/2/3+children), Alternate healthy eating index 
(AHEI) (in tertiles, 0-42.8, 42.8-51.3, ≥ 51.3), regular aspirin use (yes/no), regular non-aspirin 
NSAIDs use (yes/no), and family history of colorectal cancer (yes/no) at blood collection, and 
weight change from blood collection until 2 years before diagnosis (in tertiles, < 0 kg, 0-2.72 kg, 





















between mtDNAcn and CRC risk by anatomic subsites, including colon cancer (proximal, distal) 
and rectal cancer. Unconditional logistic regression with adjustment for matching factors and 
covariates was employed to further examine the effect of two-way interactions between 
mtDNAcn and potential confounders on the risk of CRC. The statistical significance of 
interaction was assessed using likelihood ratio test for cross-product terms of covariates and log 
(mtDNAcn).  
To minimize the reverse influence of potential undetectable tumors if any at blood 
collection on mtDNAcn, we conducted a sensitivity analysis by removing cases diagnosed within 
1 and 2 years after blood collection and their matched controls. In addition, to exclude any 
potential influence of colorectal polyps and inflammatory bowel disease (IBD) on mtDNAcn 
(especially among controls), we performed another sensitivity analysis by removing cases and 
controls who had colorectal polyps and/or IBDs before the time of CRC diagnosis. We also 
examined the association between mtDNAcn and CRC risk stratified by the follow-up time since 
blood collection to explore whether mtDNAcn has potential as a long-term predictive biomarker 
for risk of CRC. All statistical analyses were performed using SAS software, version 9.4 for 
UNIX (SAS Institute, North Carolina). All tests were two-sided and P<0.05 was considered 
statistically significant. 
RESULTS 
Basic characteristics of CRC cases (n = 324) and matched controls (n= 658) in this nested 
case-control study are presented in Table 1. Briefly, the mean age (standard deviation, SD) at 
blood collection for cases was 58.9 (6.7) years and for controls was 59.3 (6.6) years. Mean age 





















controls. Compared to controls, relatively fewer cases were regular users of aspirin or NSAIDs, 
or current users of postmenopausal hormones, while relatively more cases were current smokers, 
had family history of CRC, and consumed higher amounts of alcohol. We also present those 
basic characteristics according to mtDNAcn quartiles after age standardization among 658 
control subjects (Table 2). Briefly, compared to the women in the highest quartile, percentages 
of current smokers and participants with family history of CRC were higher, while levels of total 
physical activity (MET-hours/week) were lower among the women in the lowest quartile of 
mtDNAcn.  
For the association between mtDNAcn and CRC risk, we found that lower log-mtDNAcn 
level was significantly associated with an increased risk of CRC, with a dose-dependent 
relationship in both the crude and multivariable-adjusted models; compared to the crude model, 
results did not change materially after adjusting for a list of covariates (Table 3).  Compared to 
the highest (4th) quartile, multivariable-adjusted OR (AOR, 95% CI) was 1.10 (0.69, 1.76) for the 
3rd quartile, 1.40 (0.89, 2.19) for the 2nd quartile, and 2.19 (1.43, 3.35) for the 1st quartile (P for 
trend < 0.0001). In the further analysis of CRC by anatomic subsite, we observed a significant 
inverse association for proximal colon cancer [lowest vs. highest quartile, AOR (95% CI) =3.31 
(1.70, 6.45), P for trend = 0.0003] (Table 3). The inverse association was not statistically 
significant for distal colon cancer and rectal cancer, which may be due to the small number of 
cases with cancer at those subsites.  
In the further sensitivity analysis to test any potential influence of colorectal polyps and 
inflammatory bowel disease (IBD) on mtDNAcn/CRC, the inverse association remained 
significant after removing cases and controls who had colorectal polyps and/or IBD before CRC 





















In another sensitivity analysis examining the possible reverse influence of potential undetectable 
tumors (if any) at blood collection on mtDNAcn, the results did not change materially after 
removal of cases diagnosed within 1 and 2 years after blood collection and their matched 
controls, indicating minimal reverse causation [follow-up ≥ 1 year, lowest vs. highest quartile, 
AOR (95% CI) = 2.08 (1.33, 3.24), P for trend = 0.0006; follow-up ≥ 2 year, lowest vs. highest 
quartile, AOR (95% CI) = 1.92 (1.22, 3.02), P for trend = 0.004]. 
Moreover, we performed a stratified analysis according to the follow-up time since blood 
collection (i.e., mtDNAcn testing) (Table 4). The inverse association between mtDNAcn and 
CRC remained significant among individuals with ≥ 5 years’ follow-up since mtDNAcn testing 
[lowest vs. highest quartile, AOR (95% CI) = 1.98 (1.18, 3.33), P for trend = 0.009]. The inverse 
association was also marginally significant among those with ≥ 10 years’ follow-up [lowest vs. 
highest quartile, AOR (95% CI) = 1.92 (0.94, 3.95), P for trend = 0.06]. These data suggest that 
mtDNAcn could serve as a long-term predictive marker for the risk of CRC. 
We also examined the effect of interactions between mtDNAcn and potential 
confounders on the risk of CRC. We observed an effect modification of Alternate Healthy Eating 
Index (AHEI) on the association between mtDNAcn and CRC risk (P for interaction = 0.03). In 
the stratified analysis by AHEI, a significant inverse association between mtDNAcn and CRC 
risk was shown among individuals in the lowest AHEI (i.e., less healthy diet) tertile group 
[lowest vs. highest mtDNAcn quartile, AOR (95% CI) = 3.79 (1.77, 8.13), P for trend = 0.001]; 
the inverse associations were weaker and not statistically significant among those in the 2nd
AHEI tertile group [lowest vs. highest mtDNAcn quartile, AOR (95% CI) = 1.62 (0.79, 3.35), P 
for trend = 0.11] and 3rd AHEI tertile group [AOR (95% CI) =1.75 (0.82, 3.74), P for trend = 





















BMI, physical activity, weight change from blood collection until two years before diagnosis, 
smoking status, alcohol consumption, postmenopausal hormone use, parity, regular aspirin and 
non-aspirin NSAID use, and CRC family history (P for interactions >0.05) (data not shown).  
DISCUSSION 
In our nested case-control study, we report that pre-diagnostic leukocyte mtDNAcn was 
inversely associated with subsequent CRC risk in a dose-dependent manner. Our findings are in 
line with results from a case-control study of 444 CRC cases (mean baseline age = 58.6) and 
1,423 controls (mean baseline age = 55.2) nested within the Shanghai Women’s Health Study, in 
which Huang et al. found that lower mtDNAcn was associated with higher risk of CRC [lowest 
vs. highest tertile, OR (95% CI)=1.44 (1.06-1.94), P for trend = 0.02] (13). In another case-
control study nested within the Singapore Chinese Health Study of women and men, 
Thyagarajan et al. reported a U-shaped relationship between mtDNAcn and CRC risk among 422 
cases (mean baseline age = 66.1) and 874 controls (mean baseline age = 57.6) [lowest vs. 2nd
quartile, OR = 1.81 (1.13-2.89), highest vs. 2nd quartile, OR = 3.40 (2.15-5.36), P for 
curvilinearity < 0.0001] (14).  
Besides CRC, several other cancers have also been inversely associated with mtDNAcn 
in epidemiological studies. For example, Meng et al. studied the association between mtDNAcn 
and melanoma in a case-control study (272 cases and 293 controls) nested within the NHS, and 
found an inverse association among the high cumulative UV exposure group [low vs. high 
mtDNAcn, OR (95% CI) = 3.40 (1.46-7.92), P for trend=0.004] (16). In another study by Meng 
et al. using both NHS (women) and the Health Professionals Follow-Up Study (HPFS, men), 





















lung cancer than those with high mtDNAcn levels [median vs. high mtDNAcn, OR (95% CI) = 
2.09 (1.12-3.90)] (17). Also, Xie et al. found an inverse association between mtDNAcn and soft 
tissue sarcoma among 325 patients and 330 healthy controls (age, sex, ethnicity matched); 
among both men and women, lower mtDNAcn was associated with a significantly increased risk 
of soft tissue sarcoma [< median vs. ≥ median, AOR (95% CI) = 2.71(1.94–3.82)] (24). However, 
mixed results (including both positive and null associations) were also reported for the 
relationship between mtDNAcn and other cancers, such as renal cell carcinoma and non-
Hodgkin lymphoma (25,26). Considering the complexity of carcinogenesis, it is possible that the 
relationship between mtDNAcn and cancer risk may be site-specific, depending on the specific 
organ or tissue of origin.  
Elevated oxidative stress may affect the abundance of mitochondria and mtDNAcn as 
well as mitochondrial function (27,28). Recent evidence has shown the existence of various 
DNA-repair pathways in mitochondria, such as mismatch repair, base excision repair, 
homologous recombination and non-homologous end joining, lesion bypass, and mtDNA 
degradation (6,7). However, when the rate of oxidative damage overwhelms the ability of these 
mechanisms to repair mtDNA efficiently, mtDNA may proliferate, followed by the eventual loss 
of mtDNA (27). Specifically, when mtDNA is impaired by excessive oxidative stress, healthy 
mitochondria may first increase their DNA copy number to counteract the metabolic defects in 
injured mitochondria (27). However, when the damage exceeds the limitation of the feedback 
mechanism, increasing mtDNAcn can no longer cope with the stress. This results in a net 
decrease in mtDNAcn, because mtDNA undergoes degradation by the inner cellular enzyme 
system to prevent excessive accumulation of oxidative stress damage (28). These mechanisms 





















observed might be because extensive oxidative stress may have surpassed mitochondrial capacity 
to compensate for oxidative damage. Moreover, previous studies have demonstrated a strong 
positive association between mtDNAcn and telomere length (18,29), a crucial marker of cellular 
aging and the cumulative burden of oxidative stress (30). With each cell division telomeres 
undergo shortening, and oxidative stress could increase this erosion (31). The positive correlation 
between mtDNAcn and telomere length also implies the potential of pre-diagnostic mtDNAcn 
serving as a biomarker for predicting oxidative stress–related outcomes.  
Additionally, as a reflection of oxidative stress levels, mtDNAcn may be especially 
closely associated with risks of obesity-related cancers, such as CRC (30). Overall obesity and 
abdominal adiposity may lead to increases in oxidative stress and systemic inflammation (32), 
and have been associated with elevated CRC risk (33). Our previous work showed that in healthy 
women, mtDNAcn was inversely associated with BMI even after adjusting for telomere length 
(TL) (18). Recently, Hang et al. also found that mtDNAcn tends to decrease continuously and 
persistently with adiposity over the life course (34). In addition, other environmental exposures 
such as exercise and smoking may also be involved in the regulation of mtDNAcn (35,36). For 
example, our own group found that duration and pack-years of smoking were inversely 
associated with mtDNAcn in leukocytes, while consumption of whole fruits and intake of 
flavanones (a group of antioxidants abundant in fruits) were positively associated with mtDNAcn 
(37). Smoking and physical inactivity are well-established risk factors for CRC (9,38), while 
fruit and vegetables may reduce risk (39). These prior data suggest that mtDNAcn could be a 
marker or mediator of the accumulating environmental exposures and associated systemic 
inflammation, and may exert an indirect influence on CRC risk.  





















between mtDNAcn and CRC risk in a western population. Our study has several strengths, 
including its prospective design, long-term follow-up, pre-diagnostic assessment of mtDNAcn, 
and a comprehensive list of covariates. In addition, we include only incident CRC cases 
diagnosed after blood collection, which avoids the potential reverse influence of cancer progress 
and treatment effects on leukocyte mtDNAcn levels. In the sensitivity analysis, results barely 
changed after removing CRC cases diagnosed within 2 years after blood draw, suggesting that 
the observed association is unlikely the result of undiagnosed CRC present at blood draw.  
Notably, in our study, we observed a significant inverse association for proximal colon 
cancer but not for distal colon or rectal cancer. This may be due to the small number of cancer 
cases at the latter sites. However, research has shown that clinical, pathological/histological, and 
molecular features differ between colon and rectal cancer, as well as between distal (left side) 
and proximal (right side) colon cancer (40-42). For example, proximal colon cancers are more 
likely to be microsatellite instability-high (MSI-high) tumors, while distal colon cancers are 
more likely to be chromosomal instability-high (CIN-high) tumors (42). Also, previous research 
has demonstrated that associations between environmental factors and CRC risk may be 
modified by tumor molecular subtypes (43-45). Recently, van Osch et al. found that, compared 
to other CRC tissues, mtDNAcn was significantly lower in CRC tissues with BRAF mutation (a 
mutated gene typically in MSI-high tumors) and those with high-level microsatellite instability 
(MSI), while mtDNAcn was higher in CRC tissues with KRAS mutation (a mutated gene 
typically in CIN-high tumors) (46). Whether these molecular features interact with mtDNAcn in 
modifying risk of CRC at subsites requires further investigation.  
We acknowledged some limitations of our study. One is the relatively modest sample size 





















Another limitation is the lack of detailed clinical-pathological characteristics and molecular 
classifications of these tumors. Future research investigating the mtDNAcn/CRC relationship by 
cancer molecular subtypes according to established markers and somatic profiles is needed.  
In summary, in this nested case-control study, we found a significant inverse association 
between pre-diagnostic leukocyte mtDNAcn and CRC risk. Further investigations are warranted 
to explore whether mtDNAcn could become a valuable and long-term biomarker in evaluating 
the risk and prognosis of CRC. Importantly, additional basic experimental studies are needed to 
explore the biological mechanisms underlying the relationship between mtDNAcn and CRC 
carcinogenesis. 
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Table 1. Basic characteristics of colorectal cancer cases and controls 
in the nested case-control study within the NHS 
Characteristics Cases (n=324) Controls (n=658) 
Age at blood draw, mean (SD) 58.9 (6.7) 59.3 (6.6) 
Age at diagnosis, mean (SD) 67.4 (7.5) - 
Caucasians, % 98.2 99.7 
log-mtDNAcn, mean (SD) -0.1 (0.3) 0.01 (0.3) 
Regular users of aspirin, % 38.0 47.0 
Regular users of non-aspirin NSAIDs, % 12.7 19.8 
BMI, kg/m2, mean (SD) 25.7 (5.0) 25.6 (4.7) 
Weight change from blood collection until 2 years 
before diagnosis, kg, mean (SD) 
1.0 (6.5) 1.8 (6.9) 
Physical activity, MET-hours/wk, mean (SD) 18.1 (18.0) 18.6 (19.1) 
AHEI score, mean (SD) 46.4 (9.2) 47.3 (9.6) 
Smoking status, %     - past-smokers 39.2 42.3 
- current-smokers 17.3 12.2 
Alcohol consumption, g/d, mean (SD) 7.3 (12.3) 6.9 (10.5) 
CRC in a parent or sibling, % 17.3 15.5 
Parity,  %  - 0 child 6.5 4.4 
- 1 child 5.6 8.4 
- 2 children 25.3 23.9 
- 3+ children 62.0 62.3 
Postmenopasual status, % 86.1 88.6 
Current postmenopausal hormone use, % 34.0 43.7 
Notes: 
1. Abbreviation: BMI: Body Mass Index; AHEI: Alternate Healthy Eating Index; MET:
metabolic equivalent; 2. Values are means (SD) for continuous variables and percentages for






















Table 2. Age-standardized basic characteristics by mtDNAcn quartiles among controls in 
this nested case-control study within the NHS 
Characteristics Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Number of participants 164 165 165 164 
log-mtDNAcn, mean (SD) -0.4 (0.1) -0.1 (0.0) 0.1 (0.0) 0.5 (0.2) 
Age at blood draw, mean (SD)* 59.4 (6.9) 59.4 (6.5) 59.2 (6.4) 59.0 (6.7) 
Regular users of aspirin, % 53.1 47.3 49.4 48.9 
Regular users of non-aspirin NSAIDs, % 19.4 18.5 13.9 23.3 
BMI, kg/m2, mean (SD) 25.6 (3.4) 25.7 (3.2) 26.1 (4.1) 25.7 (4.1) 
Weight change from blood collection until 2 
years before diagnosis, kg, mean (SD) 
1.7 (5.1) 2.5 (6.6) 0.8 (4.3) 1.3 (4.2) 
Physical activity, MET-hours/wk, mean (SD) 16.9 (12.4) 18.6 (12.9) 19.2 (15.3) 20.9 (17.8) 
AHEI score, mean (SD) 48.2 (8.0) 48.3 (7.0) 48.6 (7.3) 47.3 (8.3) 
Smoking status, %     - past-smokers 46.1 40.0 44.8 43.2 
- current-smokers 13.9 13.2 7.0 9.0 
Alcohol consumption, g/d, mean (SD) 6.7 (8.2) 6.8 (7.8) 7.6 (9.0) 6.9 (8.6) 
CRC in a parent or sibling, % 19.3 17.2 16.0 16.8 
Parity (≥ 2 children), % 88.5 88.6 81.0 88.8 
Postmenopausal women, % 90.1 92.1 91.2 93.4 
Current postmenopausal hormone use, % 47.5 42.1 39.3 42.6 
Notes: 
1. Abbreviation: BMI: Body Mass Index; AHEI: Alternate Healthy Eating Index; MET:
metabolic equivalent; 2. Values are means (SD) for continuous variables and percentages for
categorical variables, and are standardized to the age distribution of the study population; 3. *






















Table 3. Associations of mtDNAcn with the risk of overall colorectal cancer, as well as 
cancers at anatomic subsites 
4th 
quartile 
3rd quartile 2nd quartile 1st quartile P for 
trend OR (95%CI) OR (95%CI) OR (95%CI) 
Colorectal cancer 
Cases/controls (324/658) 57/164 68/165 78/165 121/164 
Model 1 ref 1.22 (0.78, 1.90)  1.42 (0.93, 2.18) 2.19 (1.47, 3.27) < 0.0001 
Model 2 ref 1.10 (0.69, 1.76)  1.40 (0.89, 2.19) 2.19 (1.43, 3.35) < 0.0001 
Colon cancer 
Cases/controls (253/509) 44/132 51/119 62/128 96/130 
Model 1 ref  1.28 (0.77, 2.12) 1.50 (0.94, 2.42) 2.27 (1.45, 3.55) 0.0002 
Model 2 ref  1.15 (0.66, 1.99) 1.53 (0.92, 2.55) 2.28 (1.40, 3.71) 0.0003 
        Proximal colon cancer 
       Cases/controls (151/300) 22/76 36/72 30/78 63/74 
Model 1 ref 1.76 (0.89, 3.50) 1.50 (0.77, 2.91) 3.06 (1.67, 5.61) 0.0003 
Model 2 ref 1.71 (0.80, 3.69) 1.70 (0.82, 3.51) 3.31 (1.70, 6.45) 0.0003 
        Distal colon cancer 
     Cases/controls (90/185) 18/48 14/43 31/45 27/49 
Model 1 ref 0.87 (0.38, 2.00)  1.70 (0.81, 3.54) 1.26 (0.58, 2.74) 0.28 
Model 2 ref 0.51 (0.16, 1.56) 1.20 (0.46, 3.15) 1.15 (0.42, 3.12) 0.47 
Rectal cancer 
Cases/controls (71/149) 13/32 17/46 16/37 25/34 
Model 1 ref 1.01 (0.40, 2.58) 1.13 (0.43, 2.94) 1.90 (0.78, 4.59) 0.10 
Model 2 ref 0.73 (0.23, 2.26)  0.94 (0.30, 2.92) 1.91 (0.67, 5.46) 0.12 
Notes: 
1. Abbreviation: ref: reference group; OR: odds ratio; CI: confidence interval;
2. Model 1: Conditional logistic regression model, no covariates adjustment;
3. Model 2: Conditional logistic regression model, adjusting for body mass index (in tertiles: 0-
23.2 kg/m2, 23.2-26.6 kg/m2, ≥ 26.6 kg/m2), physical activity (in tertiles, 0-8.2, 8.2-20.2, ≥ 20.2
MET-hours/week), weight change from blood collection until 2 years before diagnosis (in
tertiles, < 0kg, 0-2.72kg, ≥ 2.72kg), smoking status (never, former, or current smokers), alcohol
consumption (in tertiles, 0-0.8 g, 0.8-5.8 g, ≥ 5.8 g per day), menopausal status and
postmenopausal hormone use (premenopausal, non-current users, current users), parity
(0/1/2/3+children), Alternate healthy eating index (AHEI) (in tertiles, 0-42.8, 42.8-51.3, ≥ 51.3),






















Table 4. Associations between mtDNAcn and colorectal cancer risk by time of follow-up 
since blood collection 
4th 
quartile 
3rd quartile 2nd quartile 1st quartile P for 
trend OR (95%CI) OR (95%CI) OR (95%CI) 
 < 5 years (n= 330) 
Cases/controls (94/236) 18/56 19/70 18/64 39/46 
Model 1 ref 0.89 (0.40, 1.97) 0.94 (0.42, 2.08) 3.03 (1.39, 6.60) 0.002 
Model 2 ref 0.80 (0.33, 1.90) 0.86 (0.36, 2.06) 3.44 (1.43, 8.27) 0.003 
 ≥ 5 years (n= 652) 
Cases/controls (230/422) 39/108 49/95 60/101 82/118 
Model 1 ref 1.47 (0.86, 2.50) 1.76 (1.06, 2.93) 1.96 (1.23, 3.13) 0.004 
Model 2 ref 1.48 (0.82, 2.66) 1.72 (0.98, 3.00) 1.98 (1.18, 3.33) 0.009 
 ≥ 8 years (n= 492) 
Cases/controls (176/316) 34/91 35/66 43/72 64/87 
Model 1 ref 1.45 (0.81, 2.62) 1.67 (0.96, 2.93)  1.95 (1.17, 3.26) 0.01 
Model 2 ref 1.58 (0.79, 3.17) 1.59 (0.82, 3.07)  2.09 (1.14, 3.83) 0.02 
 ≥ 10 years (n=339) 
Cases/controls (123/216) 23/62 25/43 32/47 43/64 
Model 1 ref 1.56 (0.77, 3.15) 1.97 (1.00, 3.90) 1.76 (0.95, 3.24) 0.07 
Model 2 ref 1.38 (0.58, 3.30) 2.13 (0.92, 4.92) 1.92 (0.94, 3.95) 0.06 
Notes: 
1. Abbreviation: ref: reference group; OR: odds ratio; CI: confidence interval;
2. Model 1: Conditional logistic regression model, no covariates adjustment;
3. Model 2: Conditional logistic regression model, adjusting for body mass index (in tertiles: 0-
23.2 kg/m2, 23.2-26.6 kg/m2, ≥ 26.6 kg/m2), physical activity (in tertiles, 0-8.2, 8.2-20.2, ≥ 20.2
MET-hours/week), weight change from blood collection until 2 years before diagnosis (in
tertiles, < 0kg, 0-2.72kg, > 2.72kg), smoking status (never, former, or current smokers), alcohol
consumption (in tertiles, 0-0.8 g, 0.8-5.8 g, ≥ 5.8 g per day), menopausal status and
postmenopausal hormone use (premenopausal, non-current users, current users), parity
(0/1/2/3+children), Alternate healthy eating index (AHEI) (in tertiles, 0-42.8, 42.8-51.3, ≥ 51.3),
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